A Phase I/II Trial Assessing Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients.
Conditions: ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer; a Germline or Somatic BRCA Mutation, or a Deleterious Alteration of Other Genes Involved in Homologous Recombination Repair (HRR) or in MSI Status Interventions: Drug: Durvalumab; Drug: Olaparib; Drug: Fulvestrant Sponsors: UNICANCER; ARCAGY- GYNECO; SOLTI Breast Cancer Research Group Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Breast Cancer | Cancer | Cancer & Oncology | Gastroschisis Repair | Genetics | HER2 | Research